



EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN OLDER PATIENTS AT NURSING HOME WITH COVID-19

M.D. Molina Mendoza¹, J. Corcuera Catalá², M. Guerrero Peña, E², Delgado Silveira¹, J. Mateos-Nozal², E. Gómez Bayona¹, E. Gemeno López¹, M. Muñoz García¹, A. Cruz Jentoft², A.M. Álvarez Díaz¹
¹Pharmacy Department. Hospital Ramón y Cajal, IRYCIS. Madrid. Spain
²Geriatrics Department. Hospital Ramón y Cajal, IRYCIS. Madrid. Spain

Background and importance

The use of the **antiviral drug nirmatrelvir/ritonavir** in nursing home patients with COVID-19 has reduced main complications, although due to the comorbidity and polypharmacy there are often problems with interactions

Aim and objectives

To evaluate the **effectiveness** and safety of nirmatrelvir/ritonavir in nursing home patients with COVID-19 infection

Material and methods

Retrospective observational study including all nursing home patients attended by a Geriatrics Liaison Unit from a hospital in Madrid between May 2022 and July 2023 and treated with nirmatrelvir/ritonavir

Effectiveness: We collected number of referrals to emergency department, hospitalizations and mortality due to COVID-19 one month after treatment with nirmatrelvir/ritonavir

Safety: Interactions and adverse events detected associated with the drug

Results

111
patients
included



- 76.6% women
- Median age 89.5 years (68-102)

- 58.6% had dementia
- 40.5% had Barthel ≤ 40

Had impaired renal function and required **reduced doses** **33.3%**


96.4% Had mild symptoms (cough, fever, myalgia, diarrhoea)

0.9% Were asymptomatic

53.2% Previously received 4 doses of vaccine

Effectiveness

97.3%



2.7% referred to the Emergency Department one month after treatment for Covid-19

Of whom 66.7% required hospital admission

No patient died during this month due to covid-19

283
interactions

- 8.8% Trazodone
- 8.1% Metamizole
- 7.4% Quetiapine
- 7.4% Amlodipine
- 6% Mirtazapine
- 4.6% Atorvastatin

One patient presented potential adverse reaction (dysgeusia)

Safety

- 62 different chronic drugs
- Mean of 2.6 interactions per patient

At least 1 interaction **93.8%**

- **82 severe interactions** Required discontinuation
- **180 moderate interactions**



81
monitoring

99 **drug adjustment**

(Including change of dose, frequency, regimen or substitution with another drug)

Conclusions

Nirmatrelvir/ritonavir is effective and safe for the treatment of covid-19 in nursing home patients but requires a review of clinical history and drug interactions to adjust chronic treatments during administration.